Table 1.
Patient characteristics.
| Total (n = 147) |
No PPIs (Cohort 1) (n = 79) |
With PPIs (Cohort 2) (n = 68) |
p-Value | |
|---|---|---|---|---|
| Sex, n (%) | 0.450 | |||
| Women | 60 (41%) | 30 (38%) | 30 (44%) | |
| Men | 87 (59%) | 49 (62%) | 38 (56%) | |
| Age at metastatic diagnosis (years) | 0.767 | |||
| Mean (SD) | 62.4 (14.9) | 62.1 (14.9) | 62.7 (14.9) | |
| Median [Min, Max] | 65 (23–89) | 64 (23–86) | 66 (27–89) | |
| Body Mass Index | 0.884 | |||
| Mean (SD) | 26.1 (10.78) | 26.6 (13.7) | 25.6 (5.5) | |
| Performance Status | 0.962 | |||
| 0 | 23 (16%) | 12 (15%) | 11 (16%) | |
| 1 | 87 (60%) | 47 (60%) | 40 (59%) | |
| 2 | 31 (21%) | 17 (22%) | 14 (21%) | |
| 3 | 5 (3%) | 2 (3%) | 3 (4%) | |
| Symptoms at pazopanib initiation | 0.739 | |||
| No | 36 (24%) | 21 (27%) | 15 (22%) | |
| Yes | 55 (38%) | 27 (35%) | 28 (41%) | |
| Pauci-symptomatic | 55 (38%) | 30 (38%) | 25 (37%) | |
| Location of primary cancer, n (%) | 0.149 | |||
| Renal | 100 (68%) | 52 (66%) | 48 (71%) | |
| Soft-tissue sarcoma | 36 (24%) | 18 (23%) | 18 (26%) | |
| Other | 11 (7%) | 9 (11%) | 2 (3%) | |
| Treatment line, n (%) | 0.770 | |||
| Locally advanced | 6 (4%) | 4 (5%) | 2 (3%) | |
| Metastatic, first line | 54 (37%) | 31 (39%) | 23 (34%) | |
| Metastatic, second line | 40 (27%) | 21 (27%) | 19 (28%) | |
| Metastatic, ≥third line | 47 (32%) | 23 (29%) | 24 (35%) | |
| Duration of treatment (months) | ||||
| Mean (SD) | 8.2 (10.2) | 9.3 (10.8) | 7.0 (9.4) | 0.086 |
| Median [Min, Max] | 4.4 [0.1; 55.0] | 5.7 [0.1; 52.7] | 3.8 [0.3; 55.0] |
PPIs: proton pump inhibitors; SD: standard deviation; [Min, Max]: [Minimum, Maximum].